BIOTECH CATALYST AI SCANNER — October WK2

NRXP — NRx Pharmaceuticals

NRx Pharmaceuticals faces an FDA PDUFA action date on Nov 10, 2026, for its Abbreviated New Drug Application covering preservative-free intravenous ketamine. The decision determines whether the company secures immediate commercial clearance to distribute formulation KETAFREE into an ongoing domestic ketamine shortage.

Company. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing NMDA platform therapeutics for suicidal depression, chronic pain, and PTSD. It generates no approved product sales, prepares KETAFREE for commercial launch, and plans a July 2027 Phase 1 trial for GNK-301 in ALS.

Science & competition. The candidate is an intravenous NMDA receptor antagonist designed to stimulate rapid synaptic repair for acute suicidal ideation. Rivals include Spravato (Janssen Pharmaceuticals, FDA-approved) and Auvelity (Axsome Therapeutics, FDA-approved). Standard of care relies on psychiatric hospitalization, electroconvulsive therapy, and antidepressant optimization.

Recent development. On September 15, 2026, the FDA Office of Generic Drugs reclassified the preservative-free ketamine ANDA filing from a Major Amendment to a Minor Amendment, confirming that review requires no substantial agency resources and locking in the November 10, 2026 goal date (nrxpharma.com).

Open company calendar →

IVVD — Invivyd

Invivyd expects topline safety and immunogenicity data from the Phase 3 DECLARATION trial of VYD2311 for COVID-19 pre-exposure prophylaxis in October (company's words; month-level precision). Designations: FTD. The readout decides whether the antibody generates sufficient neutralizing titers against circulating SARS-CoV-2 variants to support an accelerated Biologics License Application filing.

Company. Invivyd is a clinical-stage biopharmaceutical developer targeting serious viral respiratory infections with engineered monoclonal antibodies. It has no commercial product revenue, while its ongoing DECLARATION study serves as the prospective confirmatory trial for accelerated approval.

Science & competition. VYD2311 is an engineered monoclonal antibody providing pre-exposure prophylaxis by neutralizing SARS-CoV-2 spike proteins in vulnerable, immunocompromised populations. Rivals include Paxlovid (Pfizer, FDA-approved) and Sipavibart (AstraZeneca, Phase 3). Standard of care relies on oral nirmatrelvir/ritonavir or intravenous remdesivir.

Recent development. On September 29, 2026, Invivyd reported topline data from the Phase 3 LIBERTY study, where VYD2311 met primary safety and immunogenicity goals, showing 56.5% treatment-emergent adverse events versus 91.4% for an mRNA vaccine (P<0.0001) (invivyd.com).

Filing flag. Based on current operating plans and excluding future external financing, the company will not have sufficient cash to fund operating expenses and capital requirements beyond one year from the issuance date of the June 30, 2026 financial statements, leading to a conclusion that there is substantial doubt about the company's ability to continue as a going concern.

Open company calendar →

AKBA — Akebia Therapeutics

Akebia Therapeutics expects topline data from the Phase 3b VOCAL trial evaluating thrice-weekly dosing of Vafseo (vadadustat) for anemia due to chronic kidney disease in dialysis in Q4 2026 (company's words; quarter-level precision). The readout determines whether thrice-weekly administration matches standard erythropoietin-stimulating agents without undermining hemoglobin stability.

Company. Akebia is a commercial-stage biopharmaceutical company focused on kidney disease treatments. It markets Vafseo for dialysis-dependent chronic kidney disease anemia, while pipeline programs include AKB-097 in rare kidney disorders and AKB-9090 in healthy volunteer Phase 1 trials.

Science & competition. Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that simulates physiologic erythropoietin response to boost red blood cell production. Rivals include Jesduvroq (GlaxoSmithKline, FDA-approved) and Aranesp (Amgen, FDA-approved). Standard of care uses injectable erythropoiesis-stimulating agents with intravenous iron.

Market context. Because outpatient dialysis centers operate under rigid bundled payment models that favor low-cost legacy injectables, establishing clear operational compatibility through three-times-weekly dosing represents Akebia's primary commercial lever to accelerate clinical adoption before landmark survival results arrive in 2027.

Open company calendar →

ACRS — Aclaris Therapeutics

Aclaris Therapeutics expects topline results from its randomized Phase 2 trial of bosakitug in moderate-to-severe atopic dermatitis in the Fourth Quarter 2026 (company's words; quarter-level precision). The trial determines whether upstream blockade of thymic stromal lymphopoietin delivers statistically significant skin clearance and pruritus reduction over placebo.

Company. Aclaris is a clinical-stage biopharmaceutical developer targeting immuno-inflammatory diseases. The company generates no commercial drug sales, conducts Phase 1b testing for ATI-052 in atopic dermatitis, and plans fourth-quarter Phase 2b trial starts in asthma and lichen planus.

Science & competition. Bosakitug is a monoclonal antibody blocking thymic stromal lymphopoietin to halt epithelial cytokine cascades that drive neuro-immune itch and eczema. Rivals include Dupixent (Regeneron/Sanofi, Approved) and Cibinqo (Pfizer, Approved). Standard of care relies on topical corticosteroids and dupilumab.

Open company calendar →

PYXS — Pyxis Oncology

Pyxis Oncology expects updated clinical data from its Phase 1/2 combination study of micvotabart pelidotin (MICVO) with pembrolizumab in first-line recurrent or metastatic head and neck cancer in the fourth quarter of 2026 (company's words; quarter-level precision). The print evaluates whether pairing targeted antibody-drug conjugate cytotoxicity with anti-PD-1 checkpoint inhibition beats historical pembrolizumab single-agent response rates.

Company. Pyxis Oncology is a clinical-stage oncology biopharmaceutical developer focused on antibody-drug conjugates for solid tumors. It generates no commercial product revenue, partners with Merck on combination cohorts, and recently appointed Thomas Civik as Chief Executive Officer.

Science & competition. MICVO is an antibody-drug conjugate engineered to deliver a cytotoxic payload selectively to tumor tissue while sparing healthy cells. Rivals include Pembrolizumab (Merck & Co., FDA-approved) and Petosemtamab (Merus, Phase 3). Standard of care is pembrolizumab alone or with platinum/5-FU chemotherapy.

Recent development. On September 9, 2026, Pyxis published updated Phase 1 dose-expansion data for MICVO monotherapy in advanced head and neck squamous cell carcinoma, establishing dose-capping feasibility ahead of pivotal trial designs (pyxisoncology.com).

Open company calendar →

ZURA — Zura Bio

Zura Bio expects topline results from the Phase 2 TibuSHIELD trial evaluating tibulizumab in moderate-to-severe hidradenitis suppurativa in Q4 2026 (company's words; quarter-level precision). The readout determines whether dual neutralization of interleukin-17 and BAFF improves inflammatory skin lesions over placebo in 247 enrolled patients.

Company. Zura Bio is a clinical-stage immunology biopharmaceutical developer advancing multi-pathway antibodies for autoimmune disorders. The company reports no product sales, recently completed enrollment in systemic sclerosis trial TibuSURE, and prepares a Phase 2 polymyalgia rheumatica study.

Science & competition. Tibulizumab is a bispecific antibody neutralizing both interleukin-17 and B-cell activating factor to suppress tissue inflammation and chronic autoimmunity. Rivals include adalimumab (AbbVie, FDA-approved) and bimekizumab (UCB, FDA-approved). Standard of care relies on oral tetracyclines, adalimumab, or IL-17 inhibitors.

Open company calendar →

BDTX — Black Diamond Therapeutics

Black Diamond Therapeutics expects a clinical update and pivotal FDA feedback for Phase 2 silevertinib in frontline non-classical EGFR-mutant lung cancer in the fourth quarter of 2026 (company's words; quarter-level precision). The announcement determines whether the agency permits a single-arm accelerated approval path based on intracranial activity and progression-free survival.

Company. Black Diamond Therapeutics is a clinical-stage oncology biotechnology company developing MasterKey mutation inhibitors. It has no approved commercial products and prepares to initiate the randomized portion of a Phase 2 glioblastoma trial evaluating silevertinib in fourth-quarter 2026.

Science & competition. Silevertinib is an oral, brain-penetrant small molecule targeting atypical, non-classical EGFR kinase mutations. Rivals include Afatinib (Boehringer Ingelheim, FDA-approved) and Firmonertinib (ArriVent BioPharma/Allist Pharmaceuticals, Phase 3). Standard of care is afatinib or amivantamab combined with chemotherapy.

Open company calendar →

AGIO — Agios Pharmaceuticals

Agios Pharmaceuticals faces an FDA PDUFA decision on Nov 1, 2026, for its supplemental New Drug Application seeking accelerated approval of mitapivat in sickle cell disease. The sNDA is under Priority Review. The decision determines whether hemoglobin response data from the Phase 3 RISE UP trial justify commercial expansion ahead of the confirmatory REIGNITE study.

Company. Agios is a commercial-stage biopharmaceutical company focused on rare hematologic disorders. It markets mitapivat as Pyrukynd in pyruvate kinase deficiency and AQVESME in thalassemia, generating recurring product sales while expanding into sickle cell disease indications.

Science & competition. Mitapivat is an oral small-molecule allosteric activator of pyruvate kinase designed to restore red blood cell energy and decrease sickling. Rivals include Hydroxyurea (Bristol Myers Squibb/Medunik USA, Approved) and Casgevy (Vertex/CRISPR Therapeutics, Approved). Standard of care centers on oral hydroxyurea and blood transfusions.

Open company calendar →

ANNX — Annexon

Annexon expects Month 15 primary endpoint results from its Phase 3 ARCHER II trial evaluating vonaprument in geographic atrophy in the fourth quarter of 2026 (company's words; quarter-level precision). Designations: PRIME, FTD. The readout determines whether classical complement C1q inhibition prevents clinically meaningful vision loss in patients with advanced dry macular degeneration.

Company. Annexon is a clinical-stage biopharmaceutical developer creating neuroinflammatory complement therapeutics. It reports no product revenue, has enrolled patients in a geographic atrophy open-label extension study, and maintains a credit agreement with Oxford Finance.

Science & competition. Vonaprument is an intravitreal antibody fragment blocking complement C1q to halt neuroinflammation and photoreceptor synapse elimination. Rivals include Syfovre (Apellis Pharmaceuticals, FDA-approved) and Izervay (Astellas Pharma, FDA-approved). Standard of care consists of monthly or every-other-month intravitreal complement injections.

Open company calendar →

OCS — Oculis Holding

Oculis expects topline results from the precision-medicine PREDICT-1 trial of licaminlimab in dry eye disease around year-end (company's words; quarter-level precision). The trial determines whether selecting patients by TNFR1 genotype replicates substantial symptom and sign separation over vehicle in anterior eye inflammation.

Company. Oculis is a clinical-stage biopharmaceutical company focused on neuro-ophthalmology and ocular surface therapies. The company generates no drug sales, develops pipeline candidate privosegtor in optic neuropathies, and relies on cash and investments alongside a credit facility.

Science & competition. Licaminlimab is a topical anti-TNF alpha antibody fragment formulated to block TNFR1-mediated ocular surface inflammation in genetically defined individuals. Rivals include Restasis (AbbVie/Allergan, FDA-approved) and Xiidra (Bausch + Lomb, FDA-approved). Standard of care consists of lubricating artificial tears, prescription cyclosporine, and lifitegrast.

Recent development. On October 1, 2026, Oculis announced an industry partnership with the National Multiple Sclerosis Society focusing on vision protection for its neuroprotective asset privosegtor (OCS-05), distinct from the licaminlimab program (globenewswire.com).

Open company calendar →

RAPP — Rapport Therapeutics

Cash $411M, ~51 mo

Rapport Therapeutics anticipates Phase 2 topline data for RAP-219 in bipolar mania in October 2026 (company's words; month-level precision). Target enrollment was expanded and the statistical plan adjusted so the trial can potentially serve as confirmatory clinical evidence ahead of an End-of-Phase 2 FDA meeting. The company operates without approved drug revenue while advancing parallel Phase 3 studies in focal epilepsy.

Open company calendar →

FBIO — Fortress Biotech

Cash $197M, no net burn

Fortress Biotech expects Phase 2 topline results for its Triplex vaccine in adults co-infected with HIV and cytomegalovirus in late 2026 (company's words; quarter-level precision). The fully enrolled, placebo-controlled study tests whether the vector reduces cytomegalovirus-related complications. The company relies on partner milestone and royalty monetization across portfolio holdings rather than direct product commercialization.

Open company calendar →

IRD — Opus Genetics

Cash $78M, ~23 mo

Opus Genetics faces a PDUFA action date on Oct 17, 2026, for the supplemental New Drug Application of Phentolamine Ophthalmic Solution 0.75% in presbyopia, managed alongside global partner Viatris. Pivotal Phase 3 VEGA-3 data established that 27.2% of treated participants gained 15 or more letters in near visual acuity versus 11.5% on placebo (p<0.0001). Corrective reading lenses remain standard of care.

Open company calendar →

SLGL — Sol-Gel Technologies

Cash $49M (burn n/a)

Sol-Gel expects topline Phase 3 data for topical patidegib gel (SGT-610) in Gorlin syndrome in late November 2026 (company's words; month-level precision). The 113-patient vehicle-controlled study measures the prevention of new facial basal cell carcinomas over 12 months, with 102 patients completing treatment after a modest 9% dropout rate. Standard of care relies on repetitive surgical excision or oral hedgehog pathway inhibitors.

Open company calendar →

ENTA — Enanta Pharmaceuticals

Cash $202M, ~69 mo

Enanta expects Phase 1 topline data for oral KIT inhibitor EDP-978 in chronic urticaria in the fourth quarter of 2026 (company's words; quarter-level precision). The first-in-human volunteer study evaluates safety, single and multiple ascending dose pharmacokinetics, and serum tryptase reduction. Second-generation H1-antihistamines and omalizumab represent standard of care.

Open company calendar →

FTH — Faeth Therapeutics

Cash $178M, ~63 mo

Faeth Therapeutics expects topline results from the Phase 2 FTH-PIK-201 trial evaluating PIKTOR in second-line advanced endometrial cancer by year-end 2026 (company's words; quarter-level precision). The trial assesses whether an all-oral multi-node inhibitor of PI3K, AKT, and mTOR pathways arrests tumor progression. Platinum doublet chemotherapy and immune checkpoint regimens serve as standard of care.

Open company calendar →

IONS — Ionis Pharmaceuticals

Cash $2.0B, ~48 mo

Ionis faces an FDA PDUFA action date on Oct 26, 2026, for bepirovirsen in chronic hepatitis B following Priority Review and Breakthrough Therapy designation. Commercial partner GSK oversees global regulatory filings supported by Phase 3 B-Well trials demonstrating functional cure rates. Standard therapy consists of indefinite oral nucleoside or nucleotide analogues that rarely eliminate hepatitis B surface antigen.

Open company calendar →

INO — INOVIO

Cash unavailable

INOVIO approaches an FDA accelerated approval PDUFA target date of Oct 30, 2026, for its INO-3107 DNA medicine BLA in HPV-6/11-associated recurrent respiratory papillomatosis. However, in its filing acceptance letter the FDA noted, as a potential review issue, its preliminary conclusion that INOVIO had not submitted adequate information to support accelerated approval eligibility. Repeated surgical debulking remains the standard intervention.

Filing flag. In the file acceptance letter, the FDA noted as a potential review issue its preliminary conclusion that the company has not submitted adequate information to support accelerated approval eligibility.

Open company calendar →

SMMT — Summit Therapeutics

Cash $572M, ~15 mo

Summit Therapeutics faces a PDUFA action date on Nov 14, 2026, for ivonescimab combined with chemotherapy in advanced EGFR-mutated non-small cell lung cancer progressing after EGFR tyrosine kinase inhibitors. The filing is supported by multiregional Phase 3 HARMONi data showing a progression-free survival hazard ratio of 0.76. Management previously noted cash and investments were insufficient for 12 months, though AstraZeneca committed a $2.0 billion equity investment.

Filing flag. The company stated in July 2026 and April 2026 that its cash, cash equivalents, and short-term investments are not sufficient to fund planned operations for a period of at least one year from the date the financial statements are issued.

Open company calendar →

TARA — Protara Therapeutics

Cash $145M, ~26 mo

Protara Therapeutics plans to report interim dose-confirmation results from the registrational Phase 3 THRIVE-3 trial of IV Choline Chloride in 4Q 2026 (company's words; quarter-level precision). The study investigates intravenous supplementation in patients dependent on long-term parenteral nutrition. Standard management utilizes parenteral nutrition formulas that lack bioavailable choline compounding.

Open company calendar →